Saphnelo

Treatment for Systemic Lupus Erythematosus

Saphnelo is specifically indicated for the treatment of adults with moderate to severe systemic lupus erythematosus (SLE). SLE is a chronic autoimmune disease where the immune system attacks the body's own healthy tissues, leading to inflammation and damage in various organs.

How It Is Used

This medication is intended for patients who are already receiving other standard treatments for lupus. It is not used as a standalone therapy but rather as an additional treatment to help manage symptoms and reduce disease activity.

Limitations of Use

Saphnelo has certain limitations regarding who should use it. It has not been studied and is not recommended for patients with the following conditions:

• Severe active lupus nephritis: This is a serious kidney inflammation caused by lupus.
• Severe active central nervous system lupus: This involves lupus affecting the brain or spinal cord.

Mechanism of Action

Saphnelo (anifrolumab-fnia) is a monoclonal antibody, a type of protein designed to recognize and attach to specific structures in the body. It works by targeting the type I interferon receptor.

In many people with systemic lupus erythematosus (SLE), the immune system is overactive due to high levels of proteins called type I interferons. These proteins act as messengers that signal the immune system to cause inflammation. While this response is helpful for fighting viruses, in lupus patients, it causes the body to attack its own healthy tissues.

How It Targets Lupus

Saphnelo helps manage lupus symptoms through the following process:

• Binding to receptors: The medication attaches to the type I interferon receptor located on the surface of various cells throughout the body.
• Blocking signals: By binding to these receptors, Saphnelo acts like a shield, preventing type I interferons from delivering their messages to the cells.
• Reducing immune activity: When these signals are blocked, the overactive immune response is dampened. This helps to reduce the chronic inflammation and tissue damage characteristic of lupus.

Common Side Effects

Many people receiving Saphnelo experience mild to moderate side effects. These most frequently include:

• Upper respiratory tract infections, such as the common cold or sore throat
• Bronchitis
• Cough
• Infusion-related reactions, which may cause headache, nausea, vomiting, or dizziness during or shortly after the treatment

Serious Side Effects

Saphnelo affects the immune system, which can lead to more significant health concerns. Contact a healthcare provider immediately if you notice signs of a serious reaction.

• Serious Infections: This medication may increase the risk of developing severe infections, including pneumonia. It also increases the risk of shingles (herpes zoster).
• Severe Allergic Reactions: Some individuals may experience anaphylaxis or other serious allergic reactions. Symptoms can include swelling of the face, lips, or tongue, difficulty breathing, or feeling faint.
• Malignancy Risk: Medications that suppress the immune system may increase the risk of developing certain types of cancer.

Infusion reactions are most likely to occur on the day of treatment. If you experience any discomfort or unusual symptoms while receiving the medication, notify the medical staff right away.

Serious Infections

Saphnelo can lower the ability of the immune system to fight infections. This may increase the risk of developing serious or fatal bacterial, viral, or fungal infections. Common infections reported include those of the respiratory tract and urinary tract. Treatment is typically not initiated in individuals with an active, clinically significant infection. If a serious infection develops during treatment, healthcare providers may pause the medication until the infection is resolved.

Hypersensitivity Reactions

Serious allergic reactions, including anaphylaxis, have been reported with the use of Saphnelo. These reactions typically occur during or shortly after the infusion. Healthcare providers monitor for symptoms during the administration process, which may include:

• Swelling of the face, lips, or tongue
• Difficulty breathing or wheezing
• Severe rash or hives
• Dizziness or fainting

Herpes Zoster (Shingles)

There is an increased risk of herpes zoster infections (shingles) in patients treated with Saphnelo. Clinical trials showed a higher incidence of shingles in those receiving the medication compared to those receiving a placebo.

Immunizations

Live or live-attenuated vaccines should be avoided while receiving Saphnelo. Because the medication suppresses certain immune responses, the body may not respond correctly to the vaccine, or the vaccine could cause an infection. It is generally recommended that all required immunizations be updated before starting treatment.

Malignancy Risk

The impact of Saphnelo on the development of cancer is not fully known. However, medications that suppress the immune system may potentially increase the risk of certain malignancies.

Chronic Infections

The safety and efficacy of Saphnelo have not been established in patients with chronic infections such as hepatitis B, hepatitis C, or HIV. Healthcare providers typically screen for tuberculosis and other underlying infections before beginning therapy.

Pregnancy

There is limited information regarding the use of Saphnelo in pregnant individuals. Because Saphnelo is a monoclonal antibody, it is likely to be transported across the placenta as a pregnancy progresses, particularly during the second and third trimesters. It is not yet known if the drug can cause fetal harm or affect reproductive capacity.

Healthcare providers may encourage patients who become pregnant while receiving this medication to enroll in a pregnancy registry. These registries collect data to help researchers understand the effects of the drug on pregnancy outcomes and the health of the infant.

Breastfeeding

It is not known whether Saphnelo passes into human breast milk or if it has any effect on a nursing infant. When deciding whether to breastfeed while using this medication, it is important to consider the health benefits of breastfeeding alongside the clinical need for the drug and any potential risks to the child.

Before starting Saphnelo, individuals should discuss their pregnancy status or plans for breastfeeding with their healthcare provider to evaluate the potential risks and benefits based on their specific situation.

Available Forms

Saphnelo is supplied as a concentrated liquid solution in a single-dose vial. It is administered exclusively as an intravenous (IV) infusion, which means it is delivered directly into a vein.

Key characteristics of this medication form include:

• Administration: It must be prepared and given by a healthcare provider in a clinical setting.
• Preparation: The concentrated solution is diluted into an infusion bag before use.
• Single-use: Each vial is intended for a single dose only.

FDA Approval Status

The U.S. Food and Drug Administration (FDA) approved Saphnelo in July 2021. It is the first type I interferon receptor antagonist to receive regulatory approval for the treatment of lupus.

Approved Indications

Saphnelo is indicated for the treatment of adult patients with moderate to severe systemic lupus erythematosus (SLE) who are receiving standard therapy. Standard therapy typically includes medications such as corticosteroids, antimalarials, or immunosuppressants.

Limitations of Use

The FDA-approved labeling includes specific limitations for the use of this medication:

• Saphnelo has not been studied in patients with severe active lupus nephritis and is not recommended for this use.
• Saphnelo has not been studied in patients with severe active central nervous system lupus and is not recommended for this use.

Safety and Regulatory Monitoring

There are currently no boxed warnings or Risk Evaluation and Mitigation Strategies (REMS) associated with Saphnelo. Regulatory authorities require monitoring for specific safety concerns, including:

• Serious Infections: Increased risk of respiratory infections and herpes zoster (shingles).
• Hypersensitivity: Risk of serious allergic reactions, including anaphylaxis.
• Malignancy: The potential risk for the development of cancers, which is a known consideration for many immunosuppressive therapies.

Factors Influencing Cost

Saphnelo is a specialty medication administered by a healthcare professional through an intravenous (IV) infusion. Because it is not a drug you purchase at a standard pharmacy, several factors determine the final cost:

• Insurance Coverage: Most insurance plans, including Medicare and private insurance, provide coverage for Saphnelo. However, your specific plan will determine your out-of-pocket expenses, such as deductibles, copayments, or coinsurance.
• Administration Fees: The total price includes the cost of the medication and the fees charged by the clinic or hospital for the infusion procedure and facility use.
• Treatment Location: Costs may differ depending on whether you receive the infusion at a doctor's office, an independent infusion center, or a hospital outpatient department.

Financial Assistance Options

There are programs available that may help reduce the cost of Saphnelo for eligible patients:

• Co-pay Programs: The manufacturer may offer a co-pay savings program for people with commercial insurance to help cover out-of-pocket costs.
• Patient Assistance Programs: For those who are uninsured or underinsured, patient assistance programs may provide the medication at no cost or a significantly reduced rate based on financial need.

To understand your specific costs, it is recommended to contact your insurance provider and the healthcare facility where you will receive treatment for a detailed estimate.